Clinical Trial Update: A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

A multicenter, randomized Phase III trial evaluating ddEC-THP versus TCHP neoadjuvant therapy for HER2-positive breast cancer is in Phase 3 with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• TCHP
• ddEC-THP

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: HER-2 Positive Breast Cancer | Phase 3 | Status: UNKNOWN